Mallinckrodt plc, of Chesterfield, U.K., confirmed enrollment of the first patient in its phase III study of terlipressin (for injection) in subjects with hepatorenal syndrome (HRS) type 1, an acute, rare and life-threatening condition requiring hospitalization, with no currently approved therapy in the U.S. or Canada.